Facteurs associés à la conscience des troubles dans la maladie d’Alzheimer débutante et le mild cognitive impairment

Jacus, Jean-Pierre; Belorgey, Nicolas; Trivalle, C.; Gély‐Nargeot, Marie‐Christine

doi:10.1016/j.encep.2014.08.011

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Oba et al ( 2019 ), those who had no depressive symptoms were able to more accurately evaluate their memory impairment, suggesting that anosognosia should not be considered as a specific symptom of AD but as the result of an interaction between memory impairment and depression. Jacus et al ( 2015 ) found a negative correlation between the degree of ACD and apathy.…”

Section: Resultsmentioning

confidence: 99%

“…In addition to this, caregivers' sense of responsibility and commitment may also be higher in the presence of reduced ACD or anosognosia, consequently having more chances to feel depressed and alienated (Starkstein et al, 2010 ; Spalletta et al, 2012 ; Jacus et al, 2015 ; Mak et al, 2015 ; Jacus, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

“…The reciprocal relationship between anosognosia and apathy still needs to be clarified. Thirteen studies assessed the ACD as the discrepancy between subject's and informant's ratings of decline (Vogel et al, 2005;Onor et al, 2006;Ries et al, 2007;Orfei et al, 2010;Galeone et al, 2011;Spalletta et al, 2012;Maki et al, 2013;Zamboni et al, 2013;Ford et al, 2014;Jacus et al, 2015;Senturk et al, 2017;Tondelli et al, 2018;Oba et al, 2019). Four studies as the discrepancy between subjective and objective scores of cognitive functioning (O'Connell et al, 2014;Coutinho et al, 2016;Vannini et al, 2017a;Hanseeuw et al, 2020).…”

Section: Clinical Correlates Of Anosognosia In Ad Dementiamentioning

confidence: 99%

See 2 more Smart Citations

Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis

Cacciamani

Houot

Gagliardi

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Background: Identifying a poor degree of awareness of cognitive decline (ACD) could represent an early indicator of Alzheimer's disease (AD).Objectives: (1) to understand whether there is evidence of poor ACD in the pre-dementia stages of AD; (2) to summarize the main findings obtained investigating ACD in AD; (3) to propose a conceptual framework.Data Sources: We searched Scopus, Pubmed, and the reference lists for studies published up to August 2020. Original research articles must report a measure of ACD and included individuals with AD dementia, or prodromal AD (or MCI), or being at risk for AD.Data Synthesis: All studies covering preclinical, prodromal, and AD dementia were systematically reviewed. We intended to perform a meta-analysis of empirical studies on preclinical AD or prodromal AD (or MCI), to compare ACD between clinical groups. Due to the paucity of literature on preclinical AD, meta-analysis was only possible for prodromal AD (or MCI) studies.Results: We systematically reviewed 283 articles, and conducted a meta-analysis of 18 articles on prodromal AD (or MCI), showing that ACD was not significantly different between patients with amnestic and non-amnestic MCI (SMD = 0.09, p = 0.574); ACD was significantly poorer in amnestic MCI (SMD = −0.56, p = 0.001) and mild AD (SMD = −1.39, p < 0.001) than in controls; ACD was also significantly poorer in mild AD than in amnestic MCI (SMD = −0.75, p < 0.001), as well as poorer than in non-amnestic MCI (SMD = −1.00, p < 0.001). We also discuss key findings on ACD in AD, such as its neural and cognitive correlates.Conclusions and Implications: We propose that patients may be complaining of their initial subtle cognitive changes, but ACD would soon start to decrease. The individual would show mild anosognosia in the MCI stage, and severe anosognosia in dementia. The evaluation of ACD (comparing self-report to cognitive scores or to informant-report) could be useful to guide the clinician toward a timely diagnosis, and in trials targeting early-stage AD.

show abstract

Section: Resultsmentioning

confidence: 99%